You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Claims for Patent: 11,229,702

✉ Email this page to a colleague

Summary for Patent: 11,229,702

Title:	High concentration formulations of adalimumab
Abstract:	The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as “biosimilar” or “bio-better” variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.
Inventor(s):	Mark Manning, Ryan Erik Holcomb
Assignee:	Hong Kong King Friend Industrial Co Ltd
Application Number:	US15/337,519

Details for Patent 11,229,702

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	11,229,702	2036-10-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	11,229,702	2036-10-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	11,229,702	2036-10-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	September 23, 2014	11,229,702	2036-10-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	November 23, 2015	11,229,702	2036-10-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	March 09, 2016	11,229,702	2036-10-28
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	October 17, 2016	11,229,702	2036-10-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 11,229,702

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
United States of America	11583584	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.